Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
NCT ID: NCT07001553
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2025-05-28
2025-12-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
NCT07313384
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
NCT06243536
Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes
NCT05569772
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399
Liraglutide in Type 1 Diabetes
NCT01612468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Weight management
Prescribed GLP-1 agonist therapy primarily for weight management
No interventions assigned to this group
Type 2 diabetes
Prescribed GLP-1 agonist therapy primarily for glycemic management
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
* The primary reason for commencing the medication will be for diabetes or weight management
* Willing to participate in dietary recall and questionnaires
Exclusion Criteria
* used a GLP-1 agonist medication in the previous 6 months,
* unwilling or unable to provide dietary recalls
* non-English speaking.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St Vincent's Hospital Melbourne
OTHER
The University of Queensland
OTHER
Australian Catholic University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Evelyn B Parr, PhD
Role: PRINCIPAL_INVESTIGATOR
Australian Catholic University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Australian Catholic University
Fitzroy, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-4090H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.